Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples

British Journal of Cancer

Volumn 89, Issue 9, 2003, Pages 1722-1728

  Springer, I N G ^a   Terheyden, H ^a   Suhr, M A A ^b   Warnke, P ^a   Dunsche, A ^c   Tiemann, M ^a   Acil Y ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Klinikum Nord   (Germany)

^c STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

Author keywords

Collagen crosslinks; Oral squamous cell carcinoma; Pyridinoline; Tissue samples

Indexed keywords

COLLAGEN DERIVATIVE; DEOXYPYRIDINOLINE; PYRIDINOLINE;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER RECURRENCE; CANCER TISSUE; COLLAGEN DEGRADATION; CONTROLLED STUDY; CROSS LINKING; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MANDIBLE; MOUTH CARCINOMA; MUCOSA; PREDICTION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; CARCINOMA, SQUAMOUS CELL; COLLAGEN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MANDIBULAR NEOPLASMS; MIDDLE AGED; MOUTH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0344009721     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601325     Document Type: Article

References (38)

1. Acil Y, Brinckmann J, Notbohm H, Muller PK, Batge B (1996) Changes with age in the urinary excretion of hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). Scand J Clin Lab Invest 56: 275-283
2. Acil Y, Müller PK (1994) A rapid method for the isolation of the mature collagen cross-links, hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). J Chromatogr A 664: 183-188
3. Acil Y, Springer ING, Broek V, Terheyden H, Jepsen S (2002a) Effects of bone morphogenetic protein-7 stimulation on osteoblasts cultured on different biomaterials. J Cell Biochem 86: 90-98
4. Acil Y, Springer ING, Prasse JG, Hedderich J, Jepsen S (2002b) Concentration of collagen cross-links in human dentin bears no relation to the individual age. Int J Legal Med 116: 340-343
5. Acil Y, Terheyden H, Dunsche A, Fleiner B, Jepsen S (2000) Three-dimensional cultivation of human osteoblast-like cells on highly porous natural bone mineral. J Biomed Mater Res 51: 703-710
6. Body JJ, Delmas PD (1992) Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74: 471-475
7. Chow V, Yuen AP, Lam KY, Ho WK, Wei WI (2001) Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma. Head Neck 23: 286-291
8. Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, Quinn KJ, Kanis J (1999) Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 10: 311-316
9. Demers LM, Costa L, Lipton A (2000) Biochemical markers and skeletal metastases. Cancer 88: 2919-2926
10. Eyre D (1992) New biomarkers of bone resorption. J Clin Endocrinol Metab 74: 470A-470C
11. Fontana A, Delmas PD (2000) Markers of bone turnover in bone metastases. Cancer 88: 2952-2960
12. Hofele C, Schwager-Schmitt M, Volkmann M (2002) Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma - five years survival rate. Laryngorhinootologie 81: 342-345
13. Izumi M, Nakanishi Y, Takayama K, Kimotsuki K, Inoue K, Wataya H, Minami T, Hara N (2001) Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer 91: 1487-1493
14. Jepsen S, Springer ING, Buschmann A, Hedderich J, Acil Y (2003) Elevated levels of collagen cross-link residues in gingival tissues and crevicular fluid of teeth with periodontal disease. Eur J Oral Sci 111: 198-202
15. Kuo WR, Lee KW, Ho KY, Tsai SM, Chiang FY, Juan KH (1999) Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck. Kaohsiung J Med Sci 15: 152-158
16. Kurokawa H, Tsuru S, Okada M, Nakamura T, Kajiyama M (1993) Evaluation of tumor markers in patients with squamous cell carcinoma in the oral cavity. Int J Oral Maxillofac Surg 22: 35-38
17. Liubimova NV, Bronnikov II Robins SP, Trapeznikova MF, Kushlinskii NE (2000) The biochemical markers of bone remodeling in cancer patients with skeletal involvement. Vopr Onkol 46: 290-297
18. Maass JD, Niemann AM, Lippert BM, Gottschlich S, Folz BJ, Werner JA (1999) CYFRA 8/18 in head and neck cancer. Anticancer Res 19: 2699-2701
19. Marttunen MB, Hietanen P, Titinen A, Roth HJ, Viinikka L, Ylikorkala O (1999) Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. Calcif Tissue Int 65: 365-368
20. Mendelsohn J (1995) Prinzipien der Neoplasie. In Harrisons Principles of Medicine, Schmailzl KJ (ed), Vol. 2, pp 245-246. Berlin: Blackwell Wissenschafts-Verlag
21. Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL (1994) Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 151: 909-913
22. Niemann AM, Goeroegh T, Gottschlich S, Lippert BM, Werner JA (1997) Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Anticancer Res 17: 2859-2860
23. Papatheofanis FJ (1997) Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma. J Nucl Med 38: 1175-1179
24. Reichart PA, Philipsen HP (1999) Maligne Tumoren. In Oralpathologie, Rateitschak KH, Wolf HF (eds) pp 108-118. Farbatlanten der Zahnmedizin. Thieme: Stuttgart
25. Shang ZJ, Li JR, Li ZB (2002) Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma. Int J Oral Maxillofac Surg 31: 495-498
26. Silva JM, Rodriguez R, Garcia JM, Munoz C, Silva J, Dominguez G, Provencio M, Espana P, Bonilla F (2002) Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 50: 530-534
27. Springer ING, Terheyden H, Dunsche A, Czech N, Tiemann M, Hedderich J, Açil Y (2003a) Collagen crosslink excretion and staging of oral cancer. Br J Cancer 88: 1105-1110
28. Springer ING, Terheyden H, Geiß S, Härle F, Açil Y (2003b) Particulated bone-grafts - effectiveness of bone cell supply. Clin Oral Impl Res, (in press)
29. Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M (1996) Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol 156: 1691-1695
30. Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M (2001) Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19: 45-51
31. Tamura H, Ishii S, Ikeda T, Enomoto K, Kitajima M (1999) The Relationship between urinary pyridinoline, deoxypyridinoline and bone metastasis in a rat Breast Cancer Model. Breast Cancer 6: 23-28
32. Teknos TN, Cox C, Yoo S, Chepeha DB, Wolf GT, Bradford CR, Carey TE, Fisher SG (2002) Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 24: 1004-1011
33. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE (1996) Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 73: 1089-1095
34. Walne AJ, Jenkins PJ, James IT, Plowman PN (1997) Pyridinium crosslinks in the monitoring of patients with bone metastases from carcinoma of the breast. Clin Oncol 9: 30-34
35. Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, Ludwig H, Ziegler R, Seibel MJ (2001) Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84: 344-351
36. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14: 792-801
37. Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, Honda M, Yano M, Moriguchi H, Kitahara S (1997) Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer 80: 1760-1767
38. Zoller J, Fiehn W, Mende U, Hotz G (1990) The diagnostic value of the tumor markers CEA, 'Ca 19-9', 'Ca 125', 'Ca15-3' and 'SCC' for the detection of recurrent tumors in patients with tumors of the head and neck. Dtsch Z Mund Kiefer Gesichtschir 14: 254-259